SCHEMBL4124182

SCHEMBL4124182

O=C(O)N1CCN(C2c3ccccc3CC2OCc2cc(Br)cc(Br)c2)CC1

nearest known ligand 0.36

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.36
PRKG1 Q13976 2/20 0.34
ATM Q13315 1/20 0.33
TACR1 P25103 6/20 0.33
KDM4E B2RXH2 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4124184 1.00 FAAH (0.36) FAAHPRKG1ATMTACR1KDM4E
SCHEMBL4120417 0.90 ATM (0.42) FAAHPRKG1ATMTACR1KDM4E
SCHEMBL4120428 0.90 ATM (0.42) FAAHPRKG1ATMTACR1KDM4E
SCHEMBL4120422 0.90 ATM (0.42) FAAHPRKG1ATMTACR1KDM4E
SCHEMBL4127052 0.88 PRKG1 (0.40) FAAHPRKG1ATMTACR1
SCHEMBL5198821 0.88 PRKG1 (0.40) FAAHPRKG1ATMTACR1
SCHEMBL4136363 0.87 MMP9 (0.39) TACR1
SCHEMBL4119449 0.86 ATM (0.40) FAAHPRKG1ATMTACR1
SCHEMBL4119444 0.86 ATM (0.40) FAAHPRKG1ATMTACR1
SCHEMBL4128300 0.85 MTNR1B (0.39) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612061-B2 Piperazine compounds LES LABORATOIRES SERVIER (FR) 2009-11-03 US disclosed
US-20090076030-A1 Piperazine compounds LES LABORATOIRES SERVIER (FR) 2009-03-19 US disclosed
US-20090075982-A1 Piperazine compounds LES LABORATOIRES SERVIER (FR) 2009-03-19 US disclosed
US-7465733-B2 Piperazine compounds LES LABORATOIRES SERVIER (FR) 2008-12-16 US disclosed
EP-1710240-B1 Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists SERVIER LAB (FR) 2007-12-05 EP disclosed
US-20060229318-A1 Piperazine compounds LES LABORATOIRES SERVIER (FR) 2006-10-12 US disclosed
WO-2006106241-A1 PIPERAZINE DERIVATIVES AND USE THEREOF AS SEROTONIN REUPTAKE INHIBITORS OR AS NEUROKININ ANTAGONISTS LES LABORATOIRES SERVIER (FR) 2006-10-12 WO disclosed
EP-1710240-A1 Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists Les Laboratoires Servier (FR) 2006-10-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075982-A1 Piperazine compounds HTR7, HTR5A, NPY5R FAAH 1992/4885PRKG1 1286/4885ATM 3151/4885
US-20090076030-A1 Piperazine compounds HTR7, HTR5A, NPY5R FAAH 1992/4885PRKG1 1286/4885ATM 3151/4885
US-20060229318-A1 Piperazine compounds HTR7, HTR5A, NPY5R FAAH 1992/4885PRKG1 1286/4885ATM 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.